Starving cancer cells: new drug aims to boost effectiveness of common liver cancer procedure
NCT ID NCT05842174
Summary
This study is testing if adding a drug called hydroxychloroquine to a standard liver cancer treatment (TACE) makes it work better. TACE works by cutting off a tumor's blood supply to starve it. Researchers think cancer cells survive this starvation by 'eating' themselves, a process called autophagy. They want to see if hydroxychloroquine, which blocks this process, helps kill more cancer cells and keeps the tumor from coming back. The trial will enroll about 93 adults with intermediate-stage liver cancer who are not candidates for surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania, 19104-4551, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.